累及肩关节的IgG4相关性疾病一例

2019-08-29 何志伟 朱岩 樊根涛 中国骨与关节杂志

患者,男,63岁,无明显诱因出现左肩关节疼痛、肿胀伴活动受限20天入院。外院左肩部X线片(图1):左肱骨干骺端溶骨性破坏并累及关节面,周围软组织肿胀,考虑感染性病变。在外院按左肩关节感染给予抗生素抗炎治疗效果不佳,2018年5月3日入我科治疗。专科检查:左肩部皮肤完整,无明显红肿,皮温正常,局部压痛、叩击痛明显,左肩关节上抬、后伸、外展等活动受限,被动活动受限伴疼痛明显,肌力、肌张力正常。实验室检

IgG4相关性疾病(IgG4-RD)是一种可累及多器官的免疫介导的慢性炎性纤维化疾病,其主要特征包括受累脏器表现类肿瘤样炎性肿块或管腔狭窄、组织内IgG4阳性浆细胞浸润、“席纹状”纤维化、闭塞性静脉炎以及可能出现的血清IgG4水平升高等。IgG4-RD可发生于全身绝大多数器官如胰腺、肾脏、肝脏、肺及其间质、甲状腺、唾液腺、头颈部、淋巴结甚至脑垂体等,在不同器官有不同临床症状,之前该病常因为不同的症状而被误认为其它类疾病。Kamisawa等最早于2003年在自身免疫胰腺炎(AIP)的基础上首次提出IgG4-RD的系统性疾病概念,此后,IgG4-RD作为整体的疾病概念得到更广泛发现和更深入的研究。IgG4-RD极少累及骨,国内仅有1例耳部IgG4-RD病变累及颞骨的报道,国外也仅有少数几例IgG4-RD侵犯颞骨和骨髓的报道。我科确诊1例罕见的以左肱骨近端为发病部位的IgG4-RD,现报道如下。

临床资料

患者,男,63岁,无明显诱因出现左肩关节疼痛、肿胀伴活动受限20天入院。外院左肩部X线片(图1):左肱骨干骺端溶骨性破坏并累及关节面,周围软组织肿胀,考虑感染性病变。在外院按左肩关节感染给予抗生素抗炎治疗效果不佳,2018年5月3日入我科治疗。专科检查:左肩部皮肤完整,无明显红肿,皮温正常,局部压痛、叩击痛明显,左肩关节上抬、后伸、外展等活动受限,被动活动受限伴疼痛明显,肌力、肌张力正常。实验室检查:血常规无明显异常,C反应蛋白12.9mg/L升高,结核感染T细胞23.4pg/ml轻微升高。左肩关节MRI示(图2):左肩关节在位,关节面毛糙,左侧肱骨头及肌腱附着处、锁骨局部信号异常,考虑感染性病变。因患者左肱骨干骺端骨质破坏明显,累及关节面并保守抗生素治疗不佳,行左肩关节感染清创术。术中打开关节囊后见关节囊内大量炎性坏死肉芽组织充填,无明显脓性分泌物,左肱骨大结节处骨质破坏明显,有大量黄色脂肪样组织充填。术中肉芽组织及病变组织留取部分送细菌培养及药敏,余送病理学检查。



术后病理示(图3):软组织内见大量成熟IgG4阳性浆细胞浸润,伴血管纤维组织增生,变性坏死及肉芽组织形成,可见少量死骨组织。免疫组化标记:CD138(3+),κ(2+),λ(2+),IgG4(2+),IgG(1+),CD55(-),Ki-67(20%~40%)。细菌培养阴性。患者虽然结核感染T细胞升高,但是无明显全身症状,无结核病史及家族史,血常规正常,加之细菌培养因子,故排除骨结核可能。血清学检查:IgG20.7g/L增高,IgG42280mg/L增高。补体C3、C4水平正常,ANA水平正常、类风湿因子(RF)水平正常。排除类风湿性关节炎及系统性红斑狼疮后,综合血清学检查及典型的病理特征,诊断为IgG4相关性疾病,并给予泼尼松联合甲氨蝶呤治疗。治疗方案为口服泼尼松40mg/天,甲氨蝶呤15mg/周,疗程12周。治疗2周后,血清IgG降为18.4g/L,IgG4降为2090mg/L。治疗后4周,患者体温由入院时38℃恢复正常,C反应蛋白恢复正常(5.0mg/L),左肩关节活动受限及疼痛明显缓解。

讨论

IgG4-RD是一种罕见的可发生于全身多处脏器的自身免疫性疾病,而骨骼及肌腱受累更为少见。IgG4-RD病程较长,临床症状轻微,因不同的受累部位而异,但终末期可能发展至组织纤维化甚至器官衰竭。该病例累及骨及关节的IgG4-RD病程较短,症状较为显著。为了评估患者全身状况,胸部及腹部CT检查结果无异常。提示可能是原发灶为肱骨的IgG4-RD,并且骨原发性IgG4-RD可能具有溶骨性影像学表现、病程短的临床特点。18F-FDGPET/CT扫描可以更全面的评估疾病范围及治疗效果。

与其它受累器官表现典型的类肿瘤样肿块相反,IgG4-RD在骨中表现为类感染样溶骨性改变。患者关节疼痛、肿胀等临床表现较感染轻,无高热等明显全身症状,炎性指标除C反应蛋白轻微升高外无异常,抗生素治疗对其无效。一般的影像学方法对IgG4-RD与骨感染性病变难以鉴别,其诊断主要依靠病理组织学。值得注意的是,在肿瘤、炎症以及一些变态反应疾病中也有可能出现IgG4阳性浆细胞浸润及血清IgG4浓度上升的情况,所以仅根据病理及血清学不足以明确诊断IgG4-RD。目前IgG4-RD的诊断主要根据以下综合诊断标准:(1)受累器官炎性肿块或弥漫性肿胀;(2)血清学检查IgG4浓度上升;(3)病理组织学检查:IgG4阳性浆细胞>10/HPF且IgG4+/IgG细胞比例>40%。本例骨作为IgG4-RD受累器官时溶骨性表现属于诊断标准中(1)的特殊表现。部分IgG4-RD患者并不同时具备全部以上特征,因此,关于IgG4-RD的诊断应该根据以上标准结合临床实际灵活判断。

目前糖皮质激素是IgG4-RD的一线治疗药物,大多数IgG4-RD临床表现都对其有效。可以根据用药后临床表现、血清学及影像学检测选择逐渐减少剂量至维持剂量或彻底停药。一般糖皮质激素用药后症状改善显著,应当在用药后2周进行血清学评估。同时,应用糖皮质激素治疗后效果改善与否也可以帮助进一步鉴别诊断IgG4-RD与其它疾病。甲氨蝶呤等免疫抑制剂也常被应用于IgG4-RD中配合糖皮质激素使用,但目前尚无前瞻性对照研究评估证实免疫抑制剂的实际疗效。对于难治性或复发性IgG4-RD,有文献表明B细胞耗竭性药物如利妥昔单抗可能具有较好疗效,但仍需进一步验证。虽然IgG4-RD主要使用糖皮质激素治疗,但是对于累及骨的患者,由于骨没有丰富的血供达到有效药力和及时改善症状的需要,对于有手术指征的患者,手术也是重要的治疗方法。本例对于骨原发性单灶性IgG4-RD,术中病理明确病变性质,刮除清创后明显改善症状外,可同时减轻药力负担,术后2周血清IgG浓度及IgG4浓度明显下降。但是由于IgG4-RD病程较长,该患者目前随访时间短,远期疗效仍有待于长期随访。

原始出处:

何志伟,朱岩,樊根涛,钱红波.累及肩关节的IgG4相关性疾病一例[J].中国骨与关节杂志,2019,8(08):638-640.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837718, encodeId=3d7d183e718e2, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Jul 15 08:49:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349557, encodeId=dd35134955e8e, content=<a href='/topic/show?id=3b118194e7a' target=_blank style='color:#2F92EE;'>#肩关节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81947, encryptionId=3b118194e7a, topicName=肩关节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350152, encodeId=3c66135015258, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482973, encodeId=90a014829e36a, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615203, encodeId=20a21615203d9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837718, encodeId=3d7d183e718e2, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Jul 15 08:49:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349557, encodeId=dd35134955e8e, content=<a href='/topic/show?id=3b118194e7a' target=_blank style='color:#2F92EE;'>#肩关节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81947, encryptionId=3b118194e7a, topicName=肩关节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350152, encodeId=3c66135015258, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482973, encodeId=90a014829e36a, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615203, encodeId=20a21615203d9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837718, encodeId=3d7d183e718e2, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Jul 15 08:49:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349557, encodeId=dd35134955e8e, content=<a href='/topic/show?id=3b118194e7a' target=_blank style='color:#2F92EE;'>#肩关节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81947, encryptionId=3b118194e7a, topicName=肩关节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350152, encodeId=3c66135015258, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482973, encodeId=90a014829e36a, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615203, encodeId=20a21615203d9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837718, encodeId=3d7d183e718e2, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Jul 15 08:49:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349557, encodeId=dd35134955e8e, content=<a href='/topic/show?id=3b118194e7a' target=_blank style='color:#2F92EE;'>#肩关节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81947, encryptionId=3b118194e7a, topicName=肩关节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350152, encodeId=3c66135015258, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482973, encodeId=90a014829e36a, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615203, encodeId=20a21615203d9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837718, encodeId=3d7d183e718e2, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Jul 15 08:49:00 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349557, encodeId=dd35134955e8e, content=<a href='/topic/show?id=3b118194e7a' target=_blank style='color:#2F92EE;'>#肩关节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81947, encryptionId=3b118194e7a, topicName=肩关节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350152, encodeId=3c66135015258, content=<a href='/topic/show?id=0ee1951250' target=_blank style='color:#2F92EE;'>#IgG4相关性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9512, encryptionId=0ee1951250, topicName=IgG4相关性疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482973, encodeId=90a014829e36a, content=<a href='/topic/show?id=5d52950839' target=_blank style='color:#2F92EE;'>#IgG4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9508, encryptionId=5d52950839, topicName=IgG4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcbb7863836, createdName=ms5106640509429053, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615203, encodeId=20a21615203d9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Aug 31 10:49:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]

相关资讯

J Shoulder Elbow Surg:冻结肩的三种疗法比较

近期发表在 Shoulder Elbow Surg的研究称,对于冻结肩的治疗,无论是关节内注射、肩峰下注射还是液压扩张,在第6个月时,均对患者有相似的临床改善,液压扩张对患者的改善速度更快一些。研究者将86名冻结肩患者随机分为三组,分别进行关节内注射、肩峰下注射和液压扩张治疗。在治疗前、治疗后1月、3月和6月,使用VAS对患者的疼痛进行评估、简明肩关节功能测试、肩关节constant评分和被动活动

肱骨大结节骨折合并肩关节后脱位二例

患者1,男,72岁。2017年5月12日骑自行车摔伤左肩。外院行X线检查,诊断为肱骨大结节骨折,给予保守治疗。石膏固定1个月后开始功能锻炼。但一直感觉肩关节疼痛,肩关节功能差,睡眠受到严重影响。2017年8月17日就诊于北京积水潭医院,体格检查发现左肩关节前方空虚,后方饱满,前屈上举可达80°,被动外旋不能过中立位,内旋可达腰部。左肩关节主动与被动活动均明显受限。X线和CT检查发现左肩关节后脱位。

Radiology:MRI能啃得了硬骨头吗?

本研究旨在验证CT与零回波时间(ZTE)磁共振(MR)成像对肩关节在检查方式间对结构性分级及临床上相关定量指标的一致性。主要目的是表明ZTE在肩关节骨质结构成像方面的临床应用,并将结果发表在Radiology上。

关节镜下改良弹性固定Latarjet术治疗一例慢性锁定性肩关节前脱位

慢性锁定性肩关节前脱位是指肩关节前脱位3周后未复位或无法复位者,可能导致肩部肌肉进行性萎缩和肩部活动范围受限,以及继发严重血管和神经损伤。由于锁定的脱位关节与周围组织粘连严重,复位困难,通常采用切开复位或关节置换治疗,目前未见采用全关节镜下治疗成功的病例报道。2016年7月,我们采用关节镜下改良弹性固定Latarjet术治疗1例慢性锁定性肩关节前脱位患者,获得满意效果。报告如下。

肩关节色素性绒毛结节性滑膜炎合并肩袖巨大撕裂1例

患者,女,71岁,右肩疼痛、无力、活动受限1个月,加重1周入院。

手法复位罕见肩关节脱位1例

患者,女,68岁,因“车祸致右肩关节疼痛、活动受限0.5h”入院。体格检查:神志清楚,表情痛苦,右上臂上举、屈肘,方肩畸形,右肩关节弹性固定,关节盂空虚,腋窝下方可触及脱出的肱骨头,肩关节压痛(+)。右肩关节DR片提示右侧肱骨头完全脱出于关节盂下方,肱骨头朝下,肱骨干与躯干呈135°夹角(见图1);进一步行右肩关节CT及三维重建未见骨折征象(见图2)。入院诊断:右肩关节脱位———垂直型脱位。采用手